Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cAd3 Sudan ebolavirus vaccine in healthy adults
PACTR202308863634681Phase 2Recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Feb 2024
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Ebola virus disease (EVD) and Sudan ebolavirus disease (SVD) comparing cAd3-EBO S vaccine with Placebo (2 arms). Primary endpoint: Safety and tolerability of cAd3-EBO S vaccine. Started Feb 2024; status: recruiting.
02
Drugs
cAd3-EBO S
03
Conditions
Ebola virus disease (EVD)Sudan ebolavirus disease (SVD)
Beyond the preview
Go deeper on PACTR202308863634681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308863634681.